Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF10B, ABBV-621(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1046MR)

This product GTTS-WQ1046MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF10B gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_003842.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8795
UniProt ID O14763
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF10B, ABBV-621(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1046MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10800MR IVTScrip™ mRNA-Anti-G, M777-16-3(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA M777-16-3
GTTS-WQ4659MR IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-986036
GTTS-WQ3789MR IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BAY-86-6150
GTTS-WQ10954MR IVTScrip™ mRNA-Anti-HAVCR2, MBG-453(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MBG-453
GTTS-WQ4097MR IVTScrip™ mRNA-Anti-oxLDL, BI-204(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BI-204
GTTS-WQ1289MR IVTScrip™ mRNA-Anti-RGMA, ABT-555(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABT-555
GTTS-WQ10762MR IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA M-6495
GTTS-WQ4073MR IVTScrip™ mRNA-Anti-IGF, BI 836(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BI 836
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW